Regeneron Pharmaceuticals Inc

REGNNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
762.63 USD
↗ 24.29 (3.29%)AT CLOSE (11:59 AM EDT)
761.50
↘ 1.13 (0.15%)
POST MARKET (AS OF 07:50 PM EDT)
Post Market
AS OF 07:50 PM EDT
761.50
↘ 1.13 (0.15%)
🔴Market: CLOSED

Regeneron Pharmaceuticals Inc (REGN) trades at $762.63 per share. The technical outlook is "Strong Buy" and the fundamental picture shows "Neutral". Key drivers include a robust Altman Z-Score and a bearish Death Cross on the long-term moving averages. REGN is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Jul 31, 2026.

Open?$726.69
High?$764.75
Low?$724.79
Prev. Close?$738.34
Volume?1.2M
Avg. Volume?925.1K
VWAP?$750.18
Rel. Volume?1.25x
Bid / Ask
Bid?$755.00 × 40
Ask?$762.63 × 40
Spread?$7.63
Midpoint?$758.82
Valuation & Ratios
Market Cap?78.5B
Shares Out?103.0M
Float?98.3M
Float %?94.6%
P/E Ratio?18.14
P/B Ratio?2.48
EPS?$42.04
Dividend?0.48%
Ex-Dividend?2026-08-18
News
Profile
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Themes
Biotech - Drug Development›Immunology & AutoimmuneHealthcare - Oncology›Immunotherapy & Immuno-OncologyHealthcare - Genomics & Precision Medicine›Gene Therapy & Gene Editing
Employees
15.4K
Market Cap
78.5B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.regeneron.com
Listed
1991-04-02
Address
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591
Phone: (914) 847-7000
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
60
Z-Score?
100
Momentum?
48
Short Sent.?
49
Piotroski F-Score?5/9Mixed
Altman Z-Score?7.01Safe
Confidence?69%Moderate
Full Fundamental Analysis →
Short InterestModerate
Short % of Float?3.56%Low
Short Interest?3.5M
Days to Cover?4.7
Free Float98.3M
Avg Daily Volume741.2K
Settlement Date2026-07-15
Financial Health
Current Ratio?3.34Strong
Quick Ratio?2.78Strong
Cash Ratio?0.44Low
Debt/Equity?0.09Low
ValuationFAIRLY VALUEDvs 10 peers + S&P 500
Score
72/100
P/E?
Peers
88
S&P
71
18.1FAIR▾
P/B?
Peers
70
S&P
65
2.48CHEAP▾
P/S?
Peers
82
S&P
29
5.05FAIR▾
P/FCF?
Peers
63
S&P
52
20.9FAIR▾
EV/EBITDA?
Peers
50
S&P
33
18.1FAIR▾
EV/Sales?
Peers
91
S&P
35
5.07FAIR▾
Returns & Efficiency
ROE?
Peers
29
S&P
50
13.7%STRONG▾
ROA?
Peers
63
S&P
75
10.4%STRONG▾
Cash Flow & Enterprise
FCF?$3.8B
Enterprise Value?$78.8B
Fundamentals ratios updated end of day
MarketsMoversWatchlist